396

11th Annual Congress on Controversies in Ophthalmology: Europe
COPHy Congress 2020

11th Annual Congress on Controversies in Ophthalmology: Europe
COPHy Congress 2020

Datum
26.03.2020, 08:00 - 28.03.2020, 17:30
Kongress
Lisbon
Sprache
Englisch
CME Max
10 CME Punkte
Gebühren ab
360.00 EUR
Veranstalter
Comtecmed
53 Rothschild Boulevard
61000 Tel Aviv
Organisator

Comtecmed
53 Rothschild Boulevard
IL - 61000 Tel Aviv
Tel.: +972 (3) 566 6166
Fax: +972 (3) 566 6177

The 11th Annual Congress on Controversies in Ophthalmology: Europe (COPHy EU) will take place in Lisbon, Portugal, March 26-28, 2020. The COPHy EU program will be devoted to evidence-based debates and discussions amongst session moderators, speakers and the audience. This educational Congress will focus on Retina, but will discuss controversies in other related areas of ophthalmology, including neuro-ophthalmology, ocular imaging, and uveitis.
  • Basisinformation
    Datum
    26.03.2020, 08:00 - 28.03.2020, 17:30
    Kongress
    Lisbon
    Sprache
    Englisch
    CME Max
    10 CME Punkte
    Gebühren ab
    360.00 EUR
    Veranstalter
    Comtecmed
    53 Rothschild Boulevard
    61000 Tel Aviv
    Organisator

    Comtecmed
    53 Rothschild Boulevard
    IL - 61000 Tel Aviv
    Tel.: +972 (3) 566 6166
    Fax: +972 (3) 566 6177

  • VERANSTALTUNGSORT
    Epic Sana Lisboa Hotel
    Av. Eng. Duarte Pacheco 15
    1070-100 Lisbon, PT
  • Programm

    Friday, March 27, 2020

    08:00-08:30 Opening Remarks | Controversies in Ophthalmology – Asia/Australia 2020
    Program Chairs: Neil Bressler (USA), Anat Loewenstein (Israel), José Cunha-Vaz (Portugal)

    08:00

    Welcome to COPHY EU 2020
    Neil Bressler (USA)
    Anat Loewenstein (Israel)

    08:10

    Opening Remarks

    08:20

    EU2020 Recipients of Global Ophthalmology Awards Program (GOAP)
    Francesco Bandello (Italy)
    Peter Kertes (Canada)

    08:30-10:00 Opening Session | Big Controversies in Retina in 2020
    Chairs: Neil Bressler (USA), Angelo Carneiro (Portugal), Peter Kertes (Canada)

    08:30

    Debate 1:  Bevacizumab and Aflibercept are the Same as Ranibizumab for Macular Edema from Retinal Vein Occlusion (SCORE, LEAVO trials)
    Yes: Angelo Carneiro (Portugal)
    No: Usha Chakravarthy (UK)
    afterwards there will be a discussion

    09:00

    Debate 2: Treat and Extend for Neovascular AMD is Preferred to PRN
    Yes: Peter Kertes (Canada)
    No: Susan Bressler (USA)
    afterwards there will be a discussion

    09:30

    Debate 3: Proliferative Diabetic Retinopathy: Five-Year Outcomes Confirm Anti-VEGF without PRP is an Acceptable Initial Treatment
    Yes: Baruch Kuppermann (USA)
    No: Paolo Lanzetta (Italy)
    afterwards there will be a discussion

    10:00-10:30 Visit to Exhibition & Coffee and Refreshment Break

     

      HALL A HALL B

    10:30
    12:00

    Medical Retina | Neovascular ("Wet") AMD Degeneration
    Chairs: Susan Bressler (USA), Nicole Eter (Germany), Jordi Mones (Spain)

    Surgical Retina 1 | Macular Holes
    Chairs: Stratos Gotzaridis (Greece), Josep Moisseiev (Israel)

    10:30

    Debate 1: Brolucizumab Represents an Improvement over Aflibercept
    Yes: Francesco Bandello (Italy)
    No: Stela Vujosevic (Italy)
    discussion afterwards

    Debate 1: Long Standing Macular Holes Should be Treated Surgically
    Yes: Joseph Moisseiev (Israel)
    No: Stratos Gotzaridis (Greece)
    discussion afterwards

    11:00

    Debate 2: Neither OCT nor OCTA is Good Enough for Anti-VEGF Followup All of the Time-Fluorescein Angiography is Needed At Least 10% of the Time
    Yes: Susan Bressler (USA)
    No: Angela Carneiro (Portugal)
    discussion afterwards

    Debate 2: Some Cases of VMT can be Treated by Intravitreal Air or Gas Injection
    Yes: Stratos Gotzaridis (Greece)
    No: William Mieler (USA)
    discussion afterwards

    11:30

    Debate 3: Treatment of Non-exudative CNV should Begin when Detected on OCT Angiography, Even in the Absence of OCT Fluid or Fluorescein Leakage
    Yes: Francesco Bandello (Italy)
    No: Patricia Udaondo (Spain)
    discussion afterwards

    Debate 3: Vitrectomy for ERM with Clear Lens: Typically Do Lens
    Extraction Simultaneously
    Yes: Baruch Kupperman (Israel)
    No: Joseph Moisseiev (Israel)
    discussion afterwards

    12:00-13:45 Visit to Exhibition & Lunch

    12:00

    Lunch Box Pick Up 

    12:10

    Industry Sponsored Luncheon Symposium

    13:25

    Visit to Exhibition & Dessert Break

    13:45-15:00 Vision Academy in Retina 2020
    Chairs: Neil Bressler (USA), Anat Loewenstein (Israel)

    13:45

    An introduction to the Vision Academy
    Neil Bressler (USA)

    13:55

    An overview of posters presented at COPHY EU from the European 2020 recipients of the Global Ophthalmology Awards Program (GOAP)
    Peter Kertes (Canada)

    14:10

    Debate I:  Can Intravitreal Anti-VEGF Therapy be Used in Pregnant or Breastfeeding Patients?
    For: Jean-Francois Korobelnik (France)
    Against: Paolo Lanzetta (Italy)

    14:20

    Presentation of Viewpoint
    Anat Loewenstein (Israel)

    14:25

    Questions

    14:30

    Debate II: T&E Retreatment/Extension Decisions Should Differentiate Between Intraretinal and Subretinal Fluid in AMD
    Yes: Nicole Eter (Germany)
    No: José Cunha-Vaz (Portugal)

    14:40

    Presentation of Viewpoint
    Anat Loewenstein (Israel)

    14:45

    Questions

    14:50

    Looking forward with the Vision Academy
    Anat Loewenstein (Israel)

    15:00-15:30 Visit to Exhibition & Coffee and Refreshment Break

     

      HALL A HALL B

    15:30
    17:00

    Medical Retina 2 | Diabetic Macular Edema (DME)
    Chairs: Luis Arias (Spain), José Cunha-Vaz (Portugal), Paolo Lanzetta (Italy)

    Glaucoma
    Chairs: Francesca Cordeiro (UK), Tony Hommer (Austria)

    15:30

    Debate 1: Corticosteroids are Warranted in the Management of Chronic DME
    Yes: José Cunha-Vaz (Portugal)
    No: Susan Bressler (USA)
    discussion afterwards

    Debate 1: There is too much Dark in the LiGHT Study
    Yes: Tony Hommer (Austria)
    No:
    discussion afterwards

    16:00

    Debate 2: Vision or OCT Outcomes after Three Months Reliably Predict
    2-Year Outcomes
    Yes: Luis Arias (Spain)
    No: Paolo Lanzetta (Italy)
    discussion afterwards

    Debate 2: The Trabecular Mesh Work is not a Viable target in Glaucoma
    Yes: Joao Barbosa Breda (Portugal)
    No:
    discussion afterwards

    16:30

    Debate 3: Ang2-inhibition Offers Long-Term Sustained Treatment
    Benefits For DME
    Yes: Sandrine Zweifel (Switzerland)
    No: Patricia Udaondo (Spain)
    discussion afterwards

    Debate 3:AI has no Place in Glaucoma Practice
    Yes: Francesca Cordeiro (UK)
    No: Joao Barbosa Breda (Portugal)
    discussion afterwards

    17:00-18:00 Industry-Sponsored Symposium

     

    Saturday, March 28, 2020

      HALL A HALL B

    07:45-09:00 Industry-Sponsored Symposium

    09:00
    10:30

    Medical Retina 3 | Potentially Longer Acting Agents
    Chairs: Francesco Bandello (Italy), Usha Chakravarthy (UK), Stela Vujosevic (Italy)

    NEURO-OPHTHALMOLOGY 1 | The Afferent Pathway
    Chairs: Pedro Fonseca (Portugal), Neil Miller (USA)

    09:00

    Debate 1: Port Deliver Systems Represents An Incremental Improvement in AMD
    Yes: Eugene de Juan (USA)
    No: Stephan Michels (Switzerland)
    discussion afterwards

    Debate 1: Patients with Acute Optic Neuritis Typically Should Have an Assay for Anti-Aquaporin-4 Antibodies, Anti-MOG Antibodies, or Both
    Yes: Eduardo Silva (PortugaL)
    No: Pedro Fonseca (Portugal)
    discussion afterwards

    09:30

    Debate 2: Faricimab Represents An Improvement in DME
    Yes: Jean-Francois Korobelnik (France)
    No: Stela Vujosevic (Italy)
    discussion afterwards

    Debate 2: Patients with "Typical" Acute Optic Neuritis Usually Should be
    Treated with IV Methylprednisolone
    Yes: Neil Miller (USA)
    No: Dalia Meira (Portugal)
    discussion afterwards

    10:00

    Debate 3: Abicipar Represents an Improvement in the Treatment of AMD
    Yes: Baruch Kuppermann (USA)
    No: Jean-Francois Korobelnik (France)
    discussion afterwards

    Case Presentations
    Moderator: Neil Miller (USA)
    Panelists: All Speakers
    1. A Young Man with Loss of Vision After Blunt Head Trauma
    2. A Young Man With Painless Bilateral Sequential Visual Loss
    3. A Child With Decreased Vision
    4. An Older Woman With Sudden Painless Visual Loss
    5. An Older Man With Episodes Of Transient Monocular Visual Loss

    10:30-11:00 Visit to Exhibition& Coffee and Refreshment Break

    11:00
    12:30

    Medical Retina 4 | AMD and Hereditary Retinal Degeneration Topics
    Chairs: Jean-Francois Korobelnik (France), Hendrik Scholl (Switzerland) Rufino
    Silva (Portugal)

    TUMORS | Ocular Melanoma
    Chairs: Bertil Damato (UK), Mandeep Sagoo (UK)

    11:00

    Debate 1: Gene Therapy is a Promising Strategy in in the Management of
    Non-Neovascular AMD
    Yes: Jordi Mones (Spain)
    No: Hendrik Scholl (Switzerland)
    discussion afterwards

    Debate 1: Monitoring of Melanocytic Chroidal Tumors is Dangerous
    Yes: Bertil Damato (UK)
    No:
    discussion afterwards

    11:30

    Debate 2: Home Monitoring with OCT to Detect Onset of Choroidal
    Neovascularization will Improve Visual Acuity Outcomes
    Yes: Jordi Mones (Spain)
    No: Rufino Silva (Portugal)
    discussion afterwards

    Debate 2: Randomized Clinical Trials are Needed to Evaluate IntraArterial Chemotherapy for Retinoblastoma
    Yes:
    No: Mandeep Sagoo (UK)
    discussion afterwards

     12:00

    Debate 3: Genetic Testing for Clinical Care, Not Just Research,
    Sometimes is Warranted in Pattern Dystrophy Phenotypes 
    Yes: Hendrik Scholl (Switzerland)
    No: Stephan Michels (Switzerland)
    discussion afterwards

    Debate 3: Adjunctive Treatment for Conjunctival Carcinoma Should be
    Topical Interferon and not Topical 5-FU 
    Yes: Mandeep Sagoo (UK)
    No: Bertil Damato (UK)
    discussion afterwards

    12:30-12:40 Visit to Exhibition & Lunch Box Pick Up

    12:40-14:00 Industry-Sponsored Luncheon Symposium

    14:00-14:30 Visit to Exhibition & Dessert Break

    14:30
    16:00

    Medical Retina 5 | AMD and Hereditary Retinal Degeneration Topics
    Chairs: Usha Chakravarthy (UK), Hendrik Scholl (Switzerland)

    NEURO-OPHTHALMOLOGY 2 | The Efferent Pathway and Systemic
    Disorders
    Chairs: Dalia Meira (Portugal), Eduardo Silva (Portugal)

    14:30

    Debate 1: OCT A Should be Obtained Routinely in Cases of Age-related
    Macular Degeneration
    Yes: Sandrine Zweifel (Switzerland)
    No: Nicole Eter (Germany)
    discussion afterwards

    Debate 1: A Patient With an Acute 6th Nerve Palsy Who is Over Age 50
    and Who has Vascular Risk Factors Typically Requires Neuroimaging
    Yes: Neil Miller (USA)
    No: Pedro Fonseca (Portugal)
    discussion afterwards

    15:00

    Debate 2: Ultra Wide Field Retinal Photography is Essential to Managing Diabetic Retinopathy
    Yes: Usha Chakravarthy (UK)
    No: Rufino Silva (Portugal)
    discussion afterwards

    Debate 2: A Temporal Artery Biopsy is Necessary in Almost Every
    Patient with Suspected Giant Cell Arteritis
    Yes: Pedro Fonseca (Portugal)
    No: Dalia Meira (Portugal)
    discussion afterwards

    15:30

    Debate 3: Autofluorescence Imaging, Not Fundus Photos or OCT, Should be Used to Monitor  Geographic Atrophy
    Yes: Hendrik Scholl (Switzerland)
    No:
    discussion afterwards

    Case Presentations
    Moderator: Neil Miller (USA)
    Panelists: All Speakers
    1. A Woman with Ptosis and Diplopia
    2. A Man with Ptosis and Diplopia
    3. A Child with Strabismus
    4. A Child with Funny Eye Movements
    5. A Elderly Man with Diplopia

    16:00
    17:30

    UVEITIS
    Chairs: Bahram Bodaghi (France), Zohar Habot-Wilner (Israel)

    Surgical Retina 2 | Surgical Systems
    Chairs: William Mieler (USA), Stanislao Rizzo (Italy)

    16:00

    Debate 1: Long Acting Intravitreal Corticosteroids for the Treatment of
    Noninfectious Posterior Segment Uveitis is Better than Systemic
    Treatment
    Yes: Carlos Pavesio (England)
    No: Bahram Bodaghi (France)
    discussion afterwards

    Debate 1: Voretigene Neparvovec-RZYL is a Viable Approach to
    Hereditary Retinal Degenerations
    Yes: William Mieler (USA)
    No: Francesco Boscia (Italy)
    discussion afterwards
    16:30

    Debate 2: Topical Prostaglandins May be Used in Uveitic Hypertension/Glaucoma
    Yes: Zohar Habot-Wilner (Israel)
    No: Carlos Pavesio (England)
    discussion afterwards

    Debate 2: 3D Monitors are Preferable to Surgical Microscope Systems
    Yes: Stanislao Rizzo (Italy)
    No: William Mieler (USA)
    discussion afterwards

    17:00

    Debate 3: OCT-Angiography is a Must-Have Tool for the Management of White Dot Syndromes
    Yes: Bahram Bodaghi (France)
    No: Zohar Habot-Wilner (Israel)
    discussion afterwards

    Debate 3: Vitrectomy is Warranted for Worsening Myopic Macular Schisis
    in the Absence of Vitreomacular Traction
    Yes: Stanislao Rizzo (Italy)
    No: Francesco Boscia (Italy)
    discussion afterwards

     

    Deadlines
    Abstract
    10.01.2020
    Hinweis
    Maximum 2 abstract per presenting author. Benefits for COPHy EU Abstract Submitters: • Access to attend the entire scientific program (including refreshment breaks and lunches as published) throughout the 2 days of the congress • Opportunity to network with experts in the field of ophthalmology from all over the globe • Globalizing your research • Abstracts will be published on the COPHy EU 2020 congress website List of Topics: • Medical Retina • Surgical Retina • Anterior Segment • Glaucoma • Neuro-Ophthalmology • Tumors • Uveitis Before you begin, please prepare the following information: • Title of the abstract and chosen topic • Family names and initials of all authors • Details of affiliation of all author(s); institution, city, country • Contact details of the presenting author (email, tel.,) Please note: Abstracts should not exceed 250 words and cannot include tables and graphs. About abstract submission: ALL SUBMITTED ABSTRACTS MUST BE IN ENGLISH AND FOLLOW THE STRUCTURED FORMAT BELOW: Title Purpose Methods Results Conclusions Financial Disclosure: Please indicate Yes/No Be sure that all changes, corrections and proofreading have been carried out before submitting.
  • Gebühren
    Fachärzte/-innen
    Gebühren ab
    610,00 EUR
    Early Bird bis 21.02.2020
    470,00 EUR
    Ärzte/-innen in Weiterbildung
    Gebühren ab
    490,00 EUR
    Early Bird bis 21.02.2020
    360,00 EUR
    Studenten/-innen
    Gebühren ab
    490,00 EUR
    Early Bird bis 21.02.2020
    360,00 EUR
    Sonstige
    Gebühren ab
    610,00 EUR
    Early Bird bis 21.02.2020
    470,00 EUR
    The mentioned price is for on-site registration. After the early bird date has expired the late registration price is 560 EUR.

    Full registration fees include: Participation in all scientific sessions, congress bag, program, all printed material of
  • Buchung / Anmeldung

     

    Unfortunately, you cannot book this event event on Eyefox yet. You should ask the organizer to be able to book quickly and easily on Eyefox.

    Do you know already? If you tick this event at My Events in your Member Area, you will be informed immediately when news become available!

     

     

    You are the organizer?

    Would you like to link your online registration here?

     

    Download the order form here and send it back to us via fax or email.

  • Zertifizierung
    Zertifizierung beantragt für 10 CME Punkte bei der European Accreditation Council for Continuing Medical Education (EACCME)
    The 11th Annual Congress on Controversies in Ophthalmology has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 10 European CME credits (ECMEC®s). Each medical specialist should claim only those
  • Sponsoren
    Allergan Portugal
    Bayer Portugal, Lda.

Veranstaltung teilen